{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:36:15Z","timestamp":1777448175218,"version":"3.51.4"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The COVID-19 pandemic has led to a major setback in both the health and economic sectors across the globe. The scale of the problem is enormous because we still do not have any specific anti-SARS-CoV-2 antiviral agent or vaccine. The human immune system has never been exposed to this novel virus, so the viral interactions with the human immune system are completely naive. New approaches are being studied at various levels, including animal in vitro models and human-based studies, to contain the COVID-19 pandemic as soon as possible. Many drugs are being tested for repurposing, but so far only remdesivir has shown some positive benefits based on preliminary reports, but these results also need further confirmation via ongoing trials. Otherwise, no other agents have shown an impactful response against COVID-19. Recently, research exploring the therapeutic application of mesenchymal stem cells (MSCs) in critically ill patients suffering from COVID-19 has gained momentum. The patients belonging to this subset are most likely beyond the point where they could benefit from an antiviral therapy because most of their illness at this stage of disease is driven by inflammatory (over)response of the immune system. In this review, we discuss the potential of MSCs as a therapeutic option for patients with COVID-19, based on the encouraging results from the preliminary data showing improved outcomes in the progression of COVID-19 disease.<\/jats:p>","DOI":"10.1093\/labmed\/lmaa049","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T04:30:24Z","timestamp":1592022624000},"page":"24-35","source":"Crossref","is-referenced-by-count":26,"title":["Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-6882","authenticated-orcid":false,"given":"Kamal Kant","family":"Sahu","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Department of Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Daniyal","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Department of Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Cerny","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, UMass Memorial Health Care, University of Massachusetts Medical School, Worcester, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"issue":"4","key":"2021010415100978400_CIT0001","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.4103\/jfmpc.jfmpc_424_20","article-title":"Current perspective on pandemic of COVID-19 in the United States","volume":"9","author":"Sahu","year":"2020","journal-title":"J Family Med Prim Care."},{"issue":"7798","key":"2021010415100978400_CIT0002","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature."},{"issue":"5","key":"2021010415100978400_CIT0003","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.4103\/jfmpc.jfmpc_728_20","article-title":"Preventive and treatment strategies of COVID-19: from community to clinical trials","volume":"9","author":"Sahu","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"2021010415100978400_CIT0004"},{"issue":"4","key":"2021010415100978400_CIT0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity."},{"issue":"19","key":"2021010415100978400_CIT0006","doi-asserted-by":"crossref","first-page":"e20207","DOI":"10.1097\/MD.0000000000020207","article-title":"Novel coronavirus 2019 (COVID-19): a case report and review of treatments","volume":"99","author":"Douedi","year":"2020","journal-title":"Medicine (Baltimore)."},{"key":"2021010415100978400_CIT0007","doi-asserted-by":"crossref","DOI":"10.1002\/sctm.20-0146","article-title":"Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome [published online ahead of print May 29, 2020]","author":"Qu","year":"2020","journal-title":"Stem Cells Transl Med"},{"key":"2021010415100978400_CIT0008","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3389\/fimmu.2019.01191","article-title":"Immunomodulation by Mesenchymal Stem Cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs","volume":"10","author":"Weiss","year":"2019","journal-title":"Front Immunol"},{"key":"2021010415100978400_CIT0009","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26047","article-title":"Convalescent plasma therapy: a passive therapy for an aggressive COVID-19 [published online ahead of print May 21, 2020]","author":"Sahu","year":"2020","journal-title":"J Med Virol"},{"issue":"6","key":"2021010415100978400_CIT0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jmv.25760","article-title":"Latest updates on COVID-2019: a changing paradigm shift","volume":"92","author":"Sahu","year":"2020","journal-title":"J Med Virol"},{"issue":"2","key":"2021010415100978400_CIT0011","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis."},{"issue":"3","key":"2021010415100978400_CIT0012","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12015-020-09973-w","article-title":"Mesenchymal stem cell therapy for COVID-19: present or future","volume":"16","author":"Golchin","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"2021010415100978400_CIT0013","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.medidd.2020.100019","article-title":"Mesenchymal stem cells and management of COVID-19 pneumonia","volume":"5","author":"Metcalfe","year":"2020","journal-title":"Med Drug Discov"},{"issue":"1","key":"2021010415100978400_CIT0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13287-020-01678-8","article-title":"Mesenchymal stem cells as a potential therapy for COVID-19","volume":"11","author":"Liu","year":"2020","journal-title":"Stem Cell Res Ther."},{"key":"2021010415100978400_CIT0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-bioeng-070909-105309","article-title":"Mesenchymal stem cells as therapeutics","volume":"12","author":"Parekkadan","year":"2010","journal-title":"Annu Rev Biomed Eng"},{"issue":"2","key":"2021010415100978400_CIT0016","first-page":"E71","article-title":"Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use","volume":"23","author":"Atluri","year":"2020","journal-title":"Pain Physician."},{"issue":"2","key":"2021010415100978400_CIT0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41390-019-0425-5","article-title":"Stem cell therapy for preventing neonatal diseases in the 21st century: Current understanding and challenges","volume":"87","author":"Nitkin","year":"2020","journal-title":"Pediatr Res"},{"issue":"3","key":"2021010415100978400_CIT0018","doi-asserted-by":"crossref","first-page":"477","DOI":"10.14336\/AD.2020.0403","article-title":"Mesenchymal stem cells for coronavirus (COVID-19)-induced pneumonia: revisiting the paracrine hypothesis with new hopes?","volume":"11","author":"\u00d6zt\u00fcrk","year":"2020","journal-title":"Aging Dis"},{"issue":"2","key":"2021010415100978400_CIT0019","doi-asserted-by":"crossref","first-page":"462","DOI":"10.14336\/AD.2020.0301","article-title":"Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)- induced pneumonia","volume":"11","author":"Shetty","year":"2020","journal-title":"Aging Dis."},{"issue":"3","key":"2021010415100978400_CIT0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4161\/cam.20875","article-title":"Mesenchymal stem cells in tumor development: emerging roles and concepts","volume":"6","author":"Cuiffo","year":"2012","journal-title":"Cell Adh Migr."},{"key":"2021010415100978400_CIT0021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/5584_2018_311","article-title":"Mesenchymal stem cells as regulators of carcinogenesis","volume":"1144","author":"Hayal","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"2021010415100978400_CIT0022","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMp1613723","article-title":"Clarifying stem-cell therapy\u2019s benefits and risks","volume":"376","author":"Marks","year":"2017","journal-title":"N Engl J Med."},{"key":"2021010415100978400_CIT0023"},{"key":"2021010415100978400_CIT0024"},{"key":"2021010415100978400_CIT0025"},{"key":"2021010415100978400_CIT0026","volume-title":"FDA accepts IND for NK cell therapy CYNK-001 to treat patients with COVID-19","author":"Slater","year":"2020"},{"issue":"11","key":"2021010415100978400_CIT0027","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1084\/jem.20070462","article-title":"A novel subset of putative stem\/progenitor CD34+ Oct-4 + cells is the major target for SARS coronavirus in human lung","volume":"204","author":"Chen","year":"2007","journal-title":"J Exp Med."},{"issue":"7","key":"2021010415100978400_CIT0028","doi-asserted-by":"crossref","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun Rev."},{"key":"2021010415100978400_CIT0029","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25849","article-title":"From Hematologist\u2019s desk: the effect of COVID-19 on the blood system [published online ahead of print May 1, 2020]","author":"Sahu","year":"2020","journal-title":"Am J Hematol"},{"issue":"10223","key":"2021010415100978400_CIT0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"issue":"5","key":"2021010415100978400_CIT0031","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest."},{"issue":"8","key":"2021010415100978400_CIT0032","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3642","article-title":"Lung regeneration: mechanisms, applications and emerging stem cell populations","volume":"20","author":"Kotton","year":"2014","journal-title":"Nat Med."},{"issue":"10","key":"2021010415100978400_CIT0033","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.4049\/jimmunol.0803926","article-title":"Tumor-educated CD11b high Ia low regulatory dendritic cells suppress T cell response through arginase I","volume":"182","author":"Liu","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"2021010415100978400_CIT0034","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2008-04-154138","article-title":"Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population","volume":"113","author":"Zhang","year":"2009","journal-title":"Blood."},{"issue":"3","key":"2021010415100978400_CIT0035","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.4049\/jimmunol.1102996","article-title":"Mesenchymal stem\/stromal cells induce the generation of novel IL-10\u2013dependent regulatory dendritic cells by SOCS3 activation","volume":"189","author":"Liu","year":"2012","journal-title":"J Immunol"},{"issue":"11","key":"2021010415100978400_CIT0036","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/scd.2020.0071","article-title":"Stem cell-based therapy for coronavirus disease 2019","volume":"29","author":"Zhao","year":"2020","journal-title":"Stem Cells Dev."},{"issue":"7","key":"2021010415100978400_CIT0037","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3181\/0712-RM-356","article-title":"Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue","volume":"233","author":"Rebelatto","year":"2008","journal-title":"Exp Biol Med (Maywood)."},{"issue":"1","key":"2021010415100978400_CIT0038","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12967-020-02380-2","article-title":"Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients","volume":"18","author":"Rogers","year":"2020","journal-title":"J Transl Med."},{"issue":"7","key":"2021010415100978400_CIT0039","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/14712598.2020.1761322","article-title":"Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia","volume":"20","author":"Gentile","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"2021010415100978400_CIT0040","first-page":"E71","article-title":"Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use","volume":"23","author":"Atluri","year":"2020","journal-title":"Pain Physician"},{"issue":"5","key":"2021010415100978400_CIT0041","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1634\/stemcells.2005-0342","article-title":"Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue","volume":"24","author":"Kern","year":"2006","journal-title":"Stem Cells."},{"issue":"1","key":"2021010415100978400_CIT0042","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virol.2007.09.045","article-title":"SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells","volume":"372","author":"Mossel","year":"2008","journal-title":"Virology."},{"issue":"1","key":"2021010415100978400_CIT0043","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virusres.2007.03.013","article-title":"SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium","volume":"133","author":"Sims","year":"2008","journal-title":"Virus Res."},{"issue":"6","key":"2021010415100978400_CIT0044","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1165\/rcmb.2012-0339OC","article-title":"Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus","volume":"48","author":"Qian","year":"2013","journal-title":"Am J Respir Cell Mol Biol."},{"key":"2021010415100978400_CIT0045","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19 [published online ahead of print May 6, 2020]","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"2021010415100978400_CIT0046","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.transproceed.2006.12.019","article-title":"Stem cell transplantation: the lung barrier","volume":"39","author":"Schrepfer","year":"2007","journal-title":"Transplant Proc."},{"key":"2021010415100978400_CIT0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.02.006","article-title":"Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment","author":"Chen","year":"2020","journal-title":"Engineering"},{"issue":"5","key":"2021010415100978400_CIT0048","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med."},{"issue":"4","key":"2021010415100978400_CIT0049","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med."},{"key":"2021010415100978400_CIT0050","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16880","article-title":"Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience [published online ahead of print May 23, 2020]","author":"Sahu","year":"2020","journal-title":"Br J Haematol"},{"key":"2021010415100978400_CIT0051","first-page":"1","article-title":"COVID-19 pandemic and impact on hematopoietic stem cell transplantation [published online ahead of print May 4, 2020]","author":"Sahu","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2021010415100978400_CIT0052","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12032-020-01382-w","article-title":"Cancer treatment during COVID-19 pandemic","volume":"37","author":"Jindal","year":"2020","journal-title":"Med Oncol."},{"issue":"2","key":"2021010415100978400_CIT0053","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/cc10570","article-title":"Clinical review: stem cell therapies for acute lung injury\/acute respiratory distress syndrome\u2014hope or hype?","volume":"16","author":"Hayes","year":"2012","journal-title":"Crit Care."},{"key":"2021010415100978400_CIT0054","doi-asserted-by":"crossref","first-page":"101859","DOI":"10.1016\/j.scr.2020.101859","article-title":"SARS-CoV-2 infection and stem cells: Interaction and intervention [published online ahead of print June 1, 2020]","volume":"46","author":"Yu","year":"2020","journal-title":"Stem Cell Res"},{"key":"2021010415100978400_CIT0055"},{"key":"2021010415100978400_CIT0056"},{"issue":"7","key":"2021010415100978400_CIT0057","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/0963689719837897","article-title":"The pros and cons of mesenchymal stem cell-based therapies","volume":"28","author":"Musia\u0142-Wysocka","year":"2019","journal-title":"Cell Transplant."},{"issue":"2","key":"2021010415100978400_CIT0058","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.exphem.2005.11.007","article-title":"Bone marrow production of lung cells: the impact of G-CSF, cardiotoxin, graded doses of irradiation, and subpopulation phenotype","volume":"34","author":"Aliotta","year":"2006","journal-title":"Exp Hematol."},{"issue":"2","key":"2021010415100978400_CIT0059","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1128\/JVI.01248-09","article-title":"Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63","volume":"84","author":"Glowacka","year":"2010","journal-title":"J Virol."},{"issue":"8","key":"2021010415100978400_CIT0060","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med."},{"issue":"2","key":"2021010415100978400_CIT0061","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/labmed\/article-pdf\/52\/1\/24\/35388876\/lmaa049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/labmed\/article-pdf\/52\/1\/24\/35388876\/lmaa049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T20:19:00Z","timestamp":1609791540000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/52\/1\/24\/5878411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,7,30]]},"published-print":{"date-parts":[[2021,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmaa049","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,7,30]]}}}